Symbicort in Chronic Obstructive Pulmonary Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00611520

Acronym

SYMBOL

Enrollment

64730

Registered

2008-02-11

Start date

2005-09-30

Completion date

Unknown

Last updated

2011-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

treatment of COPD, related to the budesonide/formoterole therapy in patients with COPD.

Brief summary

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with COPD treated with budesonide/formoterol

Exclusion criteria

* limitations; possible risks; warnings; contraindications mentioned in the SPC.

Design outcomes

Secondary

Measure	Time frame
to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population	—

Outcome results